Major depressive disorder: mechanism-based prescribing for personalized medicine
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Individual patients with depression present with unique symptom clusters - before, during, and even after treatment. The prevalence of persistent, unresolved symptoms and their contribution to patient functioning and disease progression emphasize the importance of finding the right treatment choice at the onset and the utility of switching medications based on suboptimal responses. Our primary goal as clinicians is to improve patient function and quality of life. In fact, feelings of well-being and the return to premorbid levels of functioning are frequently rated by patients as being more important than symptom relief. However, functional improvements often lag behind resolution of mood, attributed in large part to persistent and functionally impairing symptoms - namely, fatigue, sleep/wake disturbance, and cognitive dysfunction. Thus, patient outcomes can be optimized by deconstructing each patient's depressive profile to its component symptoms and specifically targeting those domains that differentially limit patient function. This article will provide an evidence-based framework within which clinicians may tailor pharmacotherapy to patient symptomatology for improved treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
MacDonald, A. W., Cohen, J. D., Stenger, V. A., & Carter, C. S. (2000) · Science · doi:10.1126/science.288.5472.1835 · Cited by 3,666
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241 · cited 1×
“62,71,76 Abbreviations: 5HT, 5-hydroxytryptamine or serotonin; DAT, dopamine transporter; NDRi, norepinephrine–dopamine reuptake inhibitor; NeT, norepinephrine transporter; SeRT, serotonin transporter; SNRi, serotonin–norepinephrine reuptake inhibitor; SSRi, selective serotonin reuptake inhibitor;…”
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“Aberrant DA and NE signaling is thought to adversely influence motivation, an essential driver of goal-directed behaviors and related executive functions.(65,66) Impaired 5HT neurotransmission forms, at least in part, the pathophysiologic basis for anhedonia, guilt, and similar ‘negative affects’ of depression.”
Koolschijn, P. C. M. P., van Haren, N. E. M., Lensvelt‐Mulders, G. J. L. M., Hulshoff Pol, H. E., & Kahn, R. S. (2009) · Human Brain Mapping · doi:10.1002/hbm.20801 · Cited by 902
Kessler, R. C. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.005 · Cited by 871
Penninx, B. W., Milaneschi, Y., Lamers, F., & Vogelzangs, N. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-129 · Cited by 839
McKinnon, M. C., Yucel, K., Nazarov, A., & MacQueen, G. M. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0905 · Cited by 742
Cited by
Luedtke, A., Sadikova, E., & Kessler, R. C. (2019) · Clinical Psychological Science · doi:10.1177/2167702618815466 · Cited by 143
Iosifescu, D. V., Jones, A., O’Gorman, C., Streicher, C., Feliz, S., Fava, M., & Tabuteau, H. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.21m14345 · Cited by 135
Gauthier, G., Guérin, A., Zhdanava, M., Jacobson, W., Nomikos, G., Merikle, E., François, C., & Perez, V. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1385-0 · Cited by 70
“Antidepressant drugs constitute the standard of care for MDD [6, 7, 14], whereby most patients will receive a selective serotonin reuptake inhibitor (SSRI) as first-line pharmacotherapy [15].”
BackgroundPatient-reported outcome measures for life engagement in mental health: a systematic review
McIntyre, R. S., Ismail, Z., Watling, C. P., Weiss, C., Meehan, S. R., Musingarimi, P., & Thase, M. E. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00468-5 · Cited by 48
Haghighi, M., Ludyga, S., Rahimi, B., Jahangard, L., Ahmadpanah, M., Torabian, S., Esnaashari, F., Nazaribadie, M., Bajoghli, H., Sadeghi Bahmani, D., et al. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.02.012 · Cited by 24
Metadata
- Authors
- Lapolla, T., Saltiel, P., & Silvershein, D.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2015-03
- Volume
- 11
- Pages
- 875
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W2069934545
- Cited by
- 86
- References
- 44
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Major depressive disorder: mechanism-based prescribing for personalized medicine. https://app.cochat.ai/papers/10.2147/ndt.s73261
- The paper
- Lapolla, T., Saltiel, P., & Silvershein, D. (2015). Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s73261
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.